^○Masayo FUJITA¹, Yukiko OCHIAI^{1, 2}, Taishi Clark TAKEDA¹, Yoko HAGINO¹, Kazuto KOBAYASHI³, Kazutaka IKEDA¹ (1. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2. Department of Neurology, Tokyo Metropolitan Neurological Hospital, 3. Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University )

^○Kento IGARASHI^{1, 2}, Kazuo TOMITA^{1, 2}, Koh-ichi TANAKA^{1, 2}, Yoshikazu KUWAHARA^{1, 3}, Nobuyoshi NISHIYAMA², Akihiro KURIMASA³, Tomoaki SATO¹ (1. Lab. of applied phapharmacology, Graduate school of medical and dental sciences, Kagoshima University, Kagoshima, Japan, 2. Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan, 3. Department of Radiation Biology and Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan)

^○Yukiko OCHIAI^{1, 2}, Masayo FUJITA¹, Yoko HAGINO¹, Kazuto KOBAYASHI³, Ryoichi OKIYAMA², Kazutaka IKEDA¹ (1. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2. Department of Neurology, Tokyo Metropolitan Neurological Hospital, 3. Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University)

^○Mizuki UCHIDA¹, Erika OTA¹, Akira YOSHIMI¹, Shinji KITAGAKI², Norio OZAKI³, Tomomi AIDA⁴, Kohichi TANAKA⁴, Yukihiro NODA¹ (1. Division of Clinical Sciences and Neuropsychopharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan, 2. Medicinal Chemistry, Meijo University Faculty of Pharmacy, Nagoya, Japan, 3. Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4. Laboratory of Molecular Neuroscience, Medical Research Institute, Tokyo Medical and Dental University (TMD), Tokyo, Japan)

^○Moe NIIJIMA¹, Akihiro MOURI^{1, 4}, Tomoaki TESHIGAWARA², Kazuo KUNISAWA¹, Hisayoshi KUBOTA¹, Mami HIRAKAWA¹, Yuko MORI², Masato HOSHI², Yasuko YAMAMOTO², Toshitaka NABESHIMA^{3, 4}, Kuniaki SAITO^{2, 4} (1. Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, 2. Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, 3. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, 4. Japanese Drug Organization of Appropriate Use and Research)

^○Masaki KATO, Naofumi KUNISAWA, Saki SHIMIZU, Yuika ISHIKURA, Natsuki HIRATA, Mizuki YASUNAGA, Yukihiro OHNO (Dept. Pharmacol., Osaka Univ. Pharm. Sci., Osaka, Japan)

^○Ikuko MIYAZAKI¹, Masato ASANUMA¹, Shinki MURAKAMI¹, Ryo KIKUOKA^{1, 2}, Nami ISOOKA¹, Chiharu SOGAWA³, Norio SOGAWA⁴, Yoshihisa KITAMURA² (1. Dept. of Med. Neurobiol., Okayama Univ. Grad. Sch. of Med., Dent. & Pharmaceut. Sci., 2. Dept. of Clin. Pharm., Okayama Univ. Grad. Sch. of Med., Dent. & Pharmaceut. Sci., 3. Dept. of Dent. Pharmacol., Okayama Univ. Grad. Sch. of Med., Dent. & Pharmaceut. Sci., 4. Dept. of Dent. Pharmacol., Matsumoto Dent. Univ.)